The Gold Standard
in DSA Detection
Quality the Transplant World Has Come to Rely On
Decades of clinical evidence has shown that HLA-specific antibodies lead to hyperacute antibody-mediated rejection (ABMR). Today, ABMR remains a major challenge to successful transplantation, but detection of donor-specific antibodies (DSA) is the best tool for stratifying risk. As the worldwide leader for the detection of DSA, LABScreen Single Antigen Bead is a crucial component of a complete patient management system.
In a recent study, both clinical and subclinical de novo DSA were associated with an increase in graft loss. In the subclinical de novo DSA group graft loss was delayed. The authors concluded that the association of de novo DSA with subsequent graft loss suggests that screening for DSA post-transplant and early intervention could improve graft outcomes.
Wiebe C, et al. Am J Transplant, 2015
Why Monitor for DSA?
In addition to pregnancy and transfusion stimulated antibodies, patients can form HLA antibodies in response to transplant-mismatched antigens. These antibodies are commonly referred to as donor specific antibodies (DSAs). In recent years, the literature has shown the importance of detecting DSA with enhanced sensitivity over and above traditional cellular crossmatch. In a pooled analysis of retrospective cohort studies, the presence of donor specific antibody (DSA) detected by solid phase assay, even with a negative flow cross-match, demonstrated statistical significance for increased risk for biopsy-proven ABMR and graft failure.
Better understand the role of ABMR in Transplantation.
Mohan S, et al. JASN, 2012
Advantages of LABScreen Single Antigen Beads
Proven accuracy to distinguish Class I and Class II DSA
Ideal for post-transplant antibody monitoring protocols
Only FDA and CE IVD cleared Single Antigen Bead on the market